Quick Answer
Indivior Pharmaceuticals, Inc. reported Long-Term Debt of $290.00 million for fiscal year 2025.
Indivior Pharmaceuticals, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $290.00M | -7.9% |
| 2024 | $315.00M | +32.9% |
| 2023 | $237.00M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $304.00M | — | -1.3% |
| June 30, 2025 | $308.00M | — | -1.0% |
| March 31, 2025 | $311.00M | — | -1.3% |
| December 31, 2024 | $315.00M | — | — |
- Indivior Pharmaceuticals, Inc. showed a decrease of -7.9% in Long-Term Debt compared to the prior fiscal year.
- Over the 2023–2025 period, Indivior Pharmaceuticals, Inc.’s long-term debt has grown by 22.4% (from $237.00 million to $290.00 million).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: